The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
Trump does have some powerful tools that would not require approval from U.S. Congress.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
As demand for lab monkeys continues to rise, U.S. scientists are reporting delays in research projects because they can't obtain enough animals, according to the National...Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
Jim Cramer really, really, really wants to be skeptical.
The market just keeps going higher, even though there are no new data points of consequence to explain it. What the heck is going on? People are just paying more for the same insights day after day, and the Dow, NASDAQ and keep climbing.
"I want to be more questioning, more critical of this market. But then again, that's like being skeptical of the damage that an 18-wheeler going 70 miles an hour can do to you as you stand in the middle of I-95," Cramer said.
So there's just no room for skepticism right now. Negativity is not being rewarded, except in a few situations involving social media, auto, mineral stocks and offshore drillers.
On Monday, Actavis announced that it would buy Allergan for a premium of $66 billion, or $219 a share. Then, the second largest oil service company, Halliburton, bid on the third largest, Baker Hughes.
"This has to signal some sort of top. You just don't get such dramatic overpays versus where the stocks were a short time ago without wondering about the wisdom of these deals," noted the "Mad Money" host.
Cramer sees a trend that if you stay skeptical, you lose in the short-term. If you thought the Actavis deal was too sketchy, then you missed some big profits on Tuesday. What did you really accomplish besides missing a terrific opportunity?
Read More Cramer: Hazards of skepticism
Amazon has had a run over the past few weeks. Is this the real deal?
To find out, Cramer consulted the fortune teller of the stock market—charts. He spoke with Bob Lang, a technician, founder and senior strategist at ExplosiveOptions.net, to see if this could be a great time to get in on buying more Amazon.
As we head into the holidays, this is typically a time of strength for Amazon. However, reinvigorated competitors like Wal-Mart, Target and Alibaba are putting pressure on Amazon from all sides. Can it continue to deliver?
"Bob Lang thinks that Amazon, which set a new all-time high slightly less than a year ago but is now down 20 percent year-to-date, could be ready to rebound," Cramer said.
One area where Cramer is comfortably skeptical is retail. In his experience, he knows stocks that run up in advance of earnings will trade down when they report—even if they report good numbers.
Yet, for some reason, investors didn't seem to understand why Home Depot stock dropped 2 percent on Tuesday when it announced that sales exceeded expectations.
"I blame this selloff conundrum on the run-up that started last week with the astounding success of Macy's stock, even as the guidance offered by management on the conference call was nothing to write home about," said the "Mad Money" host.
Read More Cramer: Retail stocks run amok
One stock that Cramer says could take off is Alkermes. This company is one of Cramer's favorite biopharma stocks, historically known for taking existing drugs and making them better. Alkermes specializes in drug-delivery technology, to create longer acting formulas for existing medications.
So people with diabetes, schizophrenia or bipolar disorder take their medication through extended release injections that would only need to be taken once a month.
To gain further insight on what upside could be in Alkermes' pipeline, Cramer sat down with CEO Richard Pops.
"The idea of a once a month injection for a schizophrenia patient, where we know reliably that the patient has adequate levels of medicine for an entire month is a very powerful thing. Part of the disease is patient's inability, or unwillingness, to take their medication every day," Pops said.
Though the stock market continues to climb higher, the price of energy is coming down in a big way. Cramer circled back to PPG Industries, a chemical company that has gotten out of all things commodity in order to become a pure specialty chemical player. Talk about good timing!
PPG has focused on creating value through intelligent acquisitions of companies like Comex, giving it more exposure in Latin America. Thought the company was hit badly during the slowdown fears in September, it delivered strong results when it reported in October. It's even had a 418 percent gain with reinvested dividends since Cramer first spotted it in 2009.
Cramer spoke with Charles Bunch, CEO of PPG, to find out if this recent acquisition of Comex could send the stock higher.
"We are already the leader in automotive OEM and large industrial customer, so we think it's a great fit for us, good synergies and we are going to start seeing the results in our first quarter of operation," Bunch said.
Cramer's skepticism continued into the Lightning Round, when he gave his take on a few caller favorites:
Transocean: "That is the biggest house of pain out there right now, along with Seadrill and ESV. I can't wish this one on anybody. I think this stock still has more downgrades to go, and is only 3 or 4 points from the bottom but a lot of people can't take that level of pain. You have to judge weather you can take it."
Diplomat Pharmacy: "This is a highly speculative situation. We know very little about how the company is doing, you have to have some sort of edge, and I do not."